Abstract
Identification of factors affecting platelet reactivity (PR) and high PR (HPR) or high platelet inhibition (HPI) rates while on prasugrel maintenance dose (MD) might be helpful in avoiding ischemic or bleeding complications. We retrospectively analyzed all patients (n=233) treated in our institution between April 2010 and November 2012 who had platelet function assessment pre-prasugrel and following prasugrel 10 mg MD for at least 5 days, using the Verify Now P2Y12 platelet function assay. Multiple linear regression and logistic regression models were applied to identify independent factors affecting post-prasugrel PR level, HPR and HPI status. The amount of variance in PR under prasugrel MD that could be explained by the model was 25.9% (adjusted R2), p<0.001. Pre-prasugrel treatment PR, acute coronary syndrome (ACS), prasugrel loading and smoking uniquely accounted for 10.8%, 1.3%, 3.5% and 1.2% of the observed variance, respectively. HPR and HPI were observed in 7.7% and 13.7% of the cases, respectively. On multivariate analysis, pre-prasugrel PR in the upper quartile (>313 PRU) was the only independent factor associated with HPR under prasugrel MD. In contrast, pre-prasugrel PR in the lower quartile (<242 PRU) and prasugrel loading emerged as the only independent predictors of HPI.
In patients under different clinical settings receiving prasugrel 10 mg MD a significant amount of the PR variability in response to prasugrel may be explained by pre- treatment PR level, ACS, prasugrel loading and smoking status. A high pre- treatment PR is associated with HPR, while a low pre-treatment PR and prasugrel loading predict HPI.
Keywords: Prasugrel, platelet reactivity, platelet pharmacology, pharmacodynamics.
Current Pharmaceutical Design
Title:Factors Affecting Residual Platelet Aggregation in Prasugrel Treated Patients
Volume: 19 Issue: 28
Author(s): Dimitrios Alexopoulos, Ioanna Xanthopoulou, Angelos Perperis, Argyro Siapika, Katerina Stavrou, Evropi Tsoni, Periklis Davlouros and George Hahalis
Affiliation:
Keywords: Prasugrel, platelet reactivity, platelet pharmacology, pharmacodynamics.
Abstract: Identification of factors affecting platelet reactivity (PR) and high PR (HPR) or high platelet inhibition (HPI) rates while on prasugrel maintenance dose (MD) might be helpful in avoiding ischemic or bleeding complications. We retrospectively analyzed all patients (n=233) treated in our institution between April 2010 and November 2012 who had platelet function assessment pre-prasugrel and following prasugrel 10 mg MD for at least 5 days, using the Verify Now P2Y12 platelet function assay. Multiple linear regression and logistic regression models were applied to identify independent factors affecting post-prasugrel PR level, HPR and HPI status. The amount of variance in PR under prasugrel MD that could be explained by the model was 25.9% (adjusted R2), p<0.001. Pre-prasugrel treatment PR, acute coronary syndrome (ACS), prasugrel loading and smoking uniquely accounted for 10.8%, 1.3%, 3.5% and 1.2% of the observed variance, respectively. HPR and HPI were observed in 7.7% and 13.7% of the cases, respectively. On multivariate analysis, pre-prasugrel PR in the upper quartile (>313 PRU) was the only independent factor associated with HPR under prasugrel MD. In contrast, pre-prasugrel PR in the lower quartile (<242 PRU) and prasugrel loading emerged as the only independent predictors of HPI.
In patients under different clinical settings receiving prasugrel 10 mg MD a significant amount of the PR variability in response to prasugrel may be explained by pre- treatment PR level, ACS, prasugrel loading and smoking status. A high pre- treatment PR is associated with HPR, while a low pre-treatment PR and prasugrel loading predict HPI.
Export Options
About this article
Cite this article as:
Alexopoulos Dimitrios, Xanthopoulou Ioanna, Perperis Angelos, Siapika Argyro, Stavrou Katerina, Tsoni Evropi, Davlouros Periklis and Hahalis George, Factors Affecting Residual Platelet Aggregation in Prasugrel Treated Patients, Current Pharmaceutical Design 2013; 19 (28) . https://dx.doi.org/10.2174/13816128113199990002
DOI https://dx.doi.org/10.2174/13816128113199990002 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
<i>Thespesia populnea</i>: An Ethnomedicinal, Phytochemical and Pharmacological
Review
The Natural Products Journal Coagulopathy in Type 2 Diabetes Mellitus: Pathological Mechanisms and the Role of Factor XIII-A Single Nucleotide Polymorphisms
Current Diabetes Reviews Editorial [Hot topic: Controversies in Hypertension Treatment (Guest Editors: Maciej Banach, Sverre E. Kjeldsen and Krzysztof Narkiewicz)]
Current Vascular Pharmacology The Role of Insertion Allele of Angiotensin Converting Enzyme Gene in Higher Endurance Efficiency and Some Aspects of Pathophysiological and Drug Effects
Current Medicinal Chemistry Modelling Human Disease with Pluripotent Stem Cells
Current Gene Therapy Antioxidant Effects of Natural Bioactive Compounds
Current Pharmaceutical Design Oxidative Stress in Cardiovascular Disease: A New Avenue Toward Future Therapeutic Approaches
Recent Patents on Cardiovascular Drug Discovery Exploring Modifications in Fetal Telomere Programming in Mothers Exposed to Multiple Risk Factors
Current Women`s Health Reviews Myocardial Revascularization Strategies in Diabetic Patients with Multi-Vessel Disease: CABG vs DES-Based PCI
Current Pharmaceutical Design Low Testosterone and Diabetes
Current Diabetes Reviews Network Insights into the Genes Regulated by Hepatocyte Nuclear Factor 4 in Response to Drug Induced Perturbations: A Review
Current Drug Discovery Technologies <i>In silico</i> Molecular Docking and ADME Studies of 1,3,4-Thiadiazole Derivatives in Relation to <i>in vitro</i> PON1 Activity
Current Computer-Aided Drug Design Experimental Approaches Towards Allergic Asthma Therapy-Murine Asthma Models
Recent Patents on Inflammation & Allergy Drug Discovery Hypertension in Diabetes: Optimal Pharmacotherapy
Cardiovascular & Hematological Agents in Medicinal Chemistry Amyloidogenesis of Natively Unfolded Proteins
Current Alzheimer Research A Prospective Study of the Clinical and Demographic Profile of Type 2 Diabetes Mellitus Patients Receiving Antidiabetic Drug Combinations
Current Diabetes Reviews Improving Adherence to Antipsychotic Pharmacotherapy
Current Clinical Pharmacology Syncytin and GCMa: Key Regulators in Human Placental Physiology and in Pre-Eclampsia
Current Women`s Health Reviews Associations between Adiponectin Gene Variability, Proinflammatory and Angiogenetic Markers: Implications for Microvascular Disease Development in Type 2 Diabetes Mellitus?
Current Vascular Pharmacology Type 2 Diabetes and Heart Failure: Challenges and Solutions
Current Cardiology Reviews